drugset / Trial / NCT00493363

Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia

NCT00493363

RandomizedParallel-groupOpen-labelTreatment

Summary

There are worrying signs that parasitological responses to the artemisinin drugs for uncomplicated falciparum malaria are slower than elsewhere in the world.If responses to artesunate are poor it is essential to have characterised the blood concentration profile as well as the parasitological response to differentiate resistance from abnormal pharmacokinetics. The primary objective of the study is to assess the level of resistance to artemisinin derivatives in Western Cambodia. A detailed evaluation of 2 different artesunate containing regimens in patients with uncomplicated malaria will be performed. Patients will be randomised to receive either a) Artesunate 2mg/kg/day for 7 days or b) Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4 The effect on parasite clearance and cure will be assessed in relation to blood concentrations of the antimalarial drugs ('PK-PD').

Timeline

Start
2007-06
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 2 mg/kg Oral
Subject Artesunate Small molecule 4 mg/kg Oral
Comparator Mefloquine Unknown 25 mg/kg